In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

InteKrin gets global rights to Amgen's compound for diabetes

Executive Summary

InteKrin Therapeutics (developing drugs for cancer, immunology, and metabolic conditions) has licensed exclusive worldwide development and marketing rights to Amgen's AMG131 (renamed INT131).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register